Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soheil Meshinchi

Showing results (181-190 of 218) with videos related to

Pageof 22
Sort By:
Research Square|December 23, 2024
Long-read epigenomic diagnosis and prognosis of Acute Myeloid LeukemiaJatinder Lamba, Francisco Marchi, Marieke Landwehr, et al.
Blood Advances|October 22, 2025
Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual DiseaseJason N Berman, Anupam Verma, Shelton A Viola, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AMLVivian M Liu, Megan Othus, Jasmine Naru, et al.
Leukemia|December 30, 2022
High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemiaZakia Aid, Elie Robert, Cécile K Lopez, et al.
Blood|January 9, 2010
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AMLJessica A Pollard, Todd A Alonzo, Robert B Gerbing, et al.
Haematologica|February 1, 2024
CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology GroupAndrew J Menssen, Chad A Hudson, Todd Alonzo, et al.
Nature Communications|April 23, 2025
Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemiaJuwita Werner, Alex G Lee, Chujing Zhang, et al.
Blood Advances|May 5, 2026
Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemiaNastassja Keora Scheidegger, Constanze Schneider, Gabriela Alexe, et al.
Biomarker Research|August 21, 2020
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG reportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2019
Comprehensive Transcriptome Profiling of Cryptic <i>CBFA2T3-GLIS2</i> Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML StudyJenny L Smith, Rhonda E Ries, Tiffany Hylkema, et al.
Pageof 22

Showing results (181-190 of 218) with videos related to

Sort By:
Pageof 22
Research Square|December 23, 2024
Long-read epigenomic diagnosis and prognosis of Acute Myeloid LeukemiaJatinder Lamba, Francisco Marchi, Marieke Landwehr, et al.
Blood Advances|October 22, 2025
Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual DiseaseJason N Berman, Anupam Verma, Shelton A Viola, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AMLVivian M Liu, Megan Othus, Jasmine Naru, et al.
Leukemia|December 30, 2022
High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemiaZakia Aid, Elie Robert, Cécile K Lopez, et al.
Blood|January 9, 2010
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AMLJessica A Pollard, Todd A Alonzo, Robert B Gerbing, et al.
Haematologica|February 1, 2024
CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology GroupAndrew J Menssen, Chad A Hudson, Todd Alonzo, et al.
Nature Communications|April 23, 2025
Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemiaJuwita Werner, Alex G Lee, Chujing Zhang, et al.
Blood Advances|May 5, 2026
Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemiaNastassja Keora Scheidegger, Constanze Schneider, Gabriela Alexe, et al.
Biomarker Research|August 21, 2020
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG reportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2019
Comprehensive Transcriptome Profiling of Cryptic <i>CBFA2T3-GLIS2</i> Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML StudyJenny L Smith, Rhonda E Ries, Tiffany Hylkema, et al.
Pageof 22